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See previous Q&A: http://www.biomedcentral.com/1741-7007/8/123Is the problem of antibiotic resistance getting
worse?
Yes. Resistance to antibiotics continues to be a signifi-
cant and growing medical problem across the globe. In
the US, the Centers for Disease Control recently released
a report showing that infections due to carbapenem-
resistant Enterobacteriaceae (CRE), which are associated
with mortality rates between 40% and 50%, rose from
1.2% to 4.2% over the decade from 2001 to 2011 [1].
In the clinically important Klebsiella subset of these
pathogens, the rise over the same time period was
from 1.6% to 10.4%. Carbapenems are among the last
resort antibiotics we have to treat infections of Gram-
negative bacteria and this steady erosion of their effi-
cacy is especially concerning. The cause is the spread
of genes that encode enzymes that destroy these an-
tibiotics, in particular KPC (Klebsiella pneumoniae
carbapenemase) and NDM (New Delhi metallo-beta-
lactamase) [2]. The latter has been found widespread
in the environment, including the water supply on
the Indian subcontinent [3].
Infections due to multidrug resistant Neisseria gonor-
rhea are also on the rise. Once easily treated with avai-
lable antibiotics, the emergence of drug-resistant strains
resulting in clinical failures is becoming more common.
A recent study in a Toronto clinic showed that 6.77%
of cases could not be cured with standard oral anti-
biotic therapy [4]. Outbreaks of infections caused by
multidrug and sometimes pan-resistant epidemic clones
of Acinetobacter baumannii are increasingly reported in
health care settings across the globe. The establishment of
methicillin-resistant Staphylococcus aureus (MRSA) in
the community at large as well as in hospitals is con-
tinuing; over 460,000 MRSA infections required hospi-
talization in the US in 2009 [5]. There are now circulatingCorrespondence: wrightge@mcmaster.ca
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reproduction in any medium, provided the orstrains of the tuberculosis-causing bacillus Mycobacterium
tuberculosis that are totally drug resistant (TDR) [6]. And
the list goes on…
The result of these trends has been increased attention
and alarm by clinicians and the public health commu-
nity. Sally Davies, the Chief Medical Officer of the UK,
recently called the situation apocalyptic and ranked anti-
biotic resistance as a threat as important as terrorism.
The WHO World Health Day on 7 April 2011 was fo-
cused on antibiotic resistance with the tag line ‘Antibiotic
resistance: no action today, no cure tomorrow’. The head
of the US CDC Thomas Frieden called antibiotic resis-
tance a ‘nightmare’.
Is all this hype or is the problem that bad?
It is important to realize that antibiotic resistance is a
natural phenomenon. It is the result of selection for
genetic elements in bacteria that confer the ability to
continue to grow in the presence of otherwise toxic
compounds. This evolutionary process has been going
on for as long as bacteria have had to cope with toxic
molecules; in other words, for millennia. Evidence of this
can be found in studies that show that resistance genes
are prevalent in 30,000-year-old permafrost samples, and
in bacteria living in a cave, sealed from the surface 4
million years ago [7,8]. Furthermore, the ability of bac-
teria to exchange these genes through mobile genetic
elements such as plasmids ensures that antibiotic resis-
tance traits can be spread efficiently through bacterial
communities. Recently, it has been confirmed that the
antibiotic resistance genes in environmental bacteria are
the same ones found in pathogens [9]. The prevalence of
global travel means that microbes and their resistance
genes can move with unprecedented ease. Resistance,
therefore, is ancient and widespread.
These facts conspire to make antibiotics very unusual
drugs in that their use selects for their eventual obsoles-
cence. We will therefore always be in need of new drugs
to fill the ‘pipeline’. The problem we have now is thathis is an Open Access article distributed under the terms of the Creative
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biotics coming to market or in clinical trials, certainly
not enough to address the resistance issue over the long
term. Since it can take up to a decade to get a new drug
from the lab to the pharmacy, we are not in a good place
right now and the problem will continue to get worse.Why is there a shortage of new antibiotic drugs?
The pharmaceutical industry has been responsible for
bringing all the antibiotics in current clinical use to
market over the past 70 years. They have been re-
markably good at finding new molecules, either com-
pletely synthetic ones or more often natural products
made by fungi and bacteria themselves, that serve as
starting points for antibiotic drugs. By carefully buil-
ding on these chemical scaffolds, the pharmaceutical
industry has provided us with a plentiful supply of safe
and effective antibiotics that can act on most pathogens,
for more than 70 years. It may actually be this success,
however, that is impeding new drug discovery in this
field now.
First, most of the blockbuster successful antibiotics
brought to market over the past decades are off-patent,
and as a result, are very inexpensive. This is good news
for cash-strapped health care providers and patients, but
bad news for pharmaceutical research that needs profits
to invest in fundamental discoveries that will result in
the next new drugs. Furthermore, while resistance is
growing and very serious, many of these off-patent drugs
continue to be effective in the majority of cases. Faced
with using an expensive new drug or a cheaper old one,
many clinicians opt for the less expensive option. Fur-
thermore, if clinicians feel that a new antibiotic should
be used only sparingly to forestall resistance, then the
new drug will not be used as much. The paradoxical re-
sult is a contracting market, and a concern on the part
of the company that they will not make sufficient profit
during the lifetime of the patent exclusivity to recoup
their investments and fuel new discovery.
Second, drugs today are very safe. This is the result of
the vigilance of government agencies, such as the FDA
in the US, that set the rules for drug clinical trials. In
these trials, the safety and efficacy of new drugs is as-
sessed over several sites, and often several years, and the
results adjudicated by an independent panel of experts
who decide if the experimental drug candidate has met
the criteria to be a new marketable drug. Any new drug
candidate must be rigorously proven to be safe. The
current safety standards are highly stringent and it has
been pointed out that our old antibiotics such as penicil-
lin, which has proven to be a lifesaver on a global scale,
would in all likelihood not pass current safety muster.
Furthermore, new antibiotics that target drug-resistantpathogens have some specific disadvantages under the
current regulatory system. For obvious ethical reasons,
new candidate antibiotics cannot be compared with a
placebo but instead must be compared with an effective
drug already on the market. Usually patients cannot be
pre-screened to determine whether they are infected
with an antibiotic-resistant or sensitive organism. If re-
sistant organisms are not highly prevalent in the specific
hospital site where the trial is being conducted, the new
compound may not show statistical efficacy compared
with an older one. The result then, is a requirement to
enlist very large numbers of patients to show statistical
efficacy of the new drug; this is incredibly expensive and
time-consuming.
Third, infections that require antibiotics very often
present acutely to the clinician with rather ambiguous
symptoms (fever, inflammation, and so on). Physicians,
therefore, treat patients empirically without knowing the
actual causative pathogen since it is often impossible to
wait 24 to 48 hours for traditional culture-based diag-
nostic methods, which themselves are problematic as
the causative agents are often not readily cultured. This
empirical strategy results in a desire for broad-spectrum
antibiotics, drugs that are effective against many patho-
gens. Broad-spectrum agents are also in the company’s
interest as it means that their drug will be prescribed
more, ensuring more revenue. As a result, broad-
spectrum efficacy is generally one of the important criteria
to be met in most antibiotic drug discovery campaigns,
even though a good argument can be made that such
agents promote resistance, and are associated with un-
desirable side effects, such as antibiotic-associated colitis,
due to their indiscriminate effect on the patient’s mi-
crobiome. This requirement for broad-spectrum activity
results in a significant triage of drug candidates early in
the drug discovery process, as compounds with the de-
sired traits have been shown to be quite rare.
Finally, unlike most other drugs, antibiotics are pre-
scribed for a very short term and actually cure disease.
Again, this is great news for the patient, but challenging
for a company that desires a sufficient return on its
investment. All of these issues conspire to make anti-
biotics less attractive as targets for the pharmaceutical
industry in comparison to other therapeutic areas. As
a result, many large pharmaceutical companies have
either abandoned, or greatly reduced, their antibiotic
discovery programs. This has had two direct effects.
The first is a dry antibiotic drug pipeline and the se-
cond is a diaspora of antibiotic discovery expertise. Since
these firms have either shut down antibiotic discovery
groups or re-assigned individuals to other areas, the
wealth of knowledge that was once embedded in these
teams is vanishing. As a result, it will not be easy simply
to ‘turn on the discovery tap’ even if economic and
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biotic drug development.
Is there any hope?
Paradoxically, while there is great clinical need that
will only get more acute given the inexorability of the
evolution of drug resistance, these are grim times for
the antibiotic drug discovery field [10]. The retreat of
pharmaceutical companies from this area has a direct
consequence: fewer new medicines to treat bacterial in-
fections over the short and medium term. There are, how-
ever, some reasons to be hopeful. Bedaquiline (Sirturo), a
first-in-class inhibitor of the Mycobacterium tuberculosis
ATP synthase, received FDA approval in 2012 for the
treatment of multi-drug-resistant tuberculosis. Fidaxo-
micin (Dificid) is a selective agent for Clostridium difficile
that received FDA approval in 2011 and, similarly, suro-
tomycin (Cubist) is a compound directed to C. difficile in
phase III clinical trials. These examples demonstrate that
narrow spectrum agents have their place in drug develop-
ment and can be brought to market. New agents continue
to be identified, such as Achaogen’s plazomicin, a semi-
synthetic aminoglycoside antibiotic with broad spectrum
activity that has just successfully completed phase II trials
for urinary tract infections.
An alternative approach to new antibiotic drug disco-
very is the pairing of existing drugs with antibiotic adju-
vants, compounds that increase the potency of antibiotic
drugs. This approach includes the inhibition of resis-
tance and at least two new combinations of beta-lactam
drugs with inhibitors of inactivating beta-lactamases are in
phase III clinical trials: ceftolozane/tazobactam (Cubist),
and ceftazidime/avibactam (Astra-Zeneca, Forrest). This
strategy of combining an antibiotic with other bioactive
compounds to overcome resistance and improve efficacy
can be extended to other compounds as well. For exam-
ple, a mixture of cefuroxime and the anti-platelet drug
ticlopidine (Ticlid) has unexpected and specific synergy
against MRSA [11]. There is tremendous scope for further
combinatorial innovation of this kind [12].
Finally, there is, in fact, no shortage of compounds
with antibiotic activity. Natural products of microbial
origin are particularly rich in such activities. The chal-
lenge with these compounds is that they are lousy drugs
at present. The criteria of single agents with broad spec-
trum utility, minimal resistance, general availability (oral,
intravenous and so on), and low cost that has driven anti-
biotic drug discovery over the past decades may, however,
prove too strict for the future.
To reach a turning point where new antibiotic drug
discovery will begin anew on the scale needed to meet
the challenge of evolution and resistance will require
new funding models. A good start to achieving this goal
is the Generate Antibiotic Incentives Now (GAIN) Actpassed by the US congress in 2012 [13]. It offers patent
exclusivity extensions for new antibiotics active against
resistant bacteria as well as measures to overcome clinical
trial challenges, and to fast track new drugs. Indeed, some
of the drug candidates mentioned above are benefiting
already from this initiative.
Further measures to re-tool the clinical trials require-
ments for new antibiotics have recently been tabled by
representatives of the pharmaceutical industry still active
in antibiotics research [14]. In their proposal, the authors
present a spectrum of options to reform the clinical trials
guidelines to address the specific needs of antibiotics in-
cluding a framework for predictive smaller and focused
trials along with options for disease or pathogen-specific
indications. These creative solutions offer a way forward
through the current regulatory challenges that new anti-
biotics face.
In the meantime though, we are left with an increa-
singly bare antibiotic drug cupboard.
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